Imagine a World Where metabolic balance is the norm,And patients live without compromise. " We are developing and delivering novel therapies for rare diseases to significantly improve the quality of life for patients and their families. learn more Our lead development program: two Phase 3 programs in congenital and tumor hyperinsulinism. View Our Pipeline Check out stories about how patients and their families address the day-to-day challenges of living with hyperinsulinism. View patient Voices Recent Press Releases view all Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting 03/24/26 Rezolute to Participate in the Citizens Life Sciences Conference 03/04/26 Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update 02/12/26
